10.2337/dc14-2548 69
Oral Contraceptives A single dose of an oral contraceptive combination product containing 0.03 mg ethinylestradiol and 0.15 mg levonorgestrel was administered under fed conditions and 7 hours after the dose of liraglutide at steady state
Pharmacological determinants in GLP-1RA-Associated cancer risk Differential cancer risk profiles across GLP-1RA subtypes and dosing regimens Existing studies underscore significant differences in the effect of various GLP-1RAs on the risk of specific cancers, such as pancreatic cancer [6,7,8, 26, 27]
A degraded medication delivers less active compound per unit drawn, which means your plotter overestimates your actual blood levels
In clinical studies of GLP-1RA plus SGLT2i combination therapy, the safety profile of the combination therapy was consistent with those of the individual agents, with no unexpected findings [9]
These side effects usually go away as your body gets used to the medication